End Stage Kidney Disease Clinical Trial
Official title:
Clinical Study Investigating the Performance and Compatibility Characteristics of the Baxter Hollow Fiber Dialyzer Xenium XPH 210 During On-line Hemodiafiltration
The proposed study seeks to determine the appropriate balance between the removal of undesirable small molecular substances (urea, creatinine, phosphate) and large molecular substances (ß2-m) and the retention of important substances (e.g.albumin) for the Baxter Xenium XPH dialyzer type under defined therapeutic conditions of olHDF primarily concerning filtration flow rates in relation to blood flow/plasma water flow rates. Furthermore the possibility of the removal of certain protein-bound substances shall be investigated together with the impact of increasing ultrafiltration on the parameters of the micro-inflammation.
The new high flux dialyser membrane Xenium XPH 210 from Baxter will show an considerably
increased removal of ß2-Microglobulin with olHDF in post dilution mode together with a
markedly increased removal of small molecules (urea, creatinine, phosphate). The loss of
albumin will depend on the treatment modalities. However, the albumin permeability is
tolerable over the whole range of total filtration rate selected and applied to the
patients.
Together with the albumin loss into the filtrate/dialysate a small amount of albuminbound
substances is detectable.
Parameters of micro-inflammation can be influenced by an increasing convective part of the
treatment.
;
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04319185 -
Assisted Peritoneal Dialysis: A Feasibility Study
|
N/A | |
Recruiting |
NCT06056739 -
Alio WEAR Study: Long-term Wear of the Alio Platform
|
N/A | |
Recruiting |
NCT05311956 -
Pain Reduction Using NEurostimulation Study
|
N/A | |
Enrolling by invitation |
NCT05485961 -
Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis
|
Phase 2/Phase 3 | |
Completed |
NCT02939586 -
The Effect of Haemodialysis in Sleep Apnoea
|
N/A | |
Completed |
NCT00792454 -
Reduction of Mortality Prior to and During the First 90 Days of Dialysis Through a Renal Rehabilitation Program
|
N/A | |
Recruiting |
NCT03586518 -
Validating Novel, Non-contrast Cardiac MRI Imaging in Haemodialysis Patients
|
||
Completed |
NCT02513303 -
Trial to Evaluate the Sirolimus-Eluting Collagen Implant on AV Fistula Outcomes
|
Phase 3 | |
Recruiting |
NCT05642156 -
Hemodynamics in Chronic Hemodialysis Patients Undergoing Isolated Ultrafiltration Compared to Conventional Hemodialysis
|
N/A | |
Not yet recruiting |
NCT05774392 -
An Observational Study of Patients With Chronic Kidney Disease
|
||
Completed |
NCT01877863 -
The Effect of Intradialytic Exercise on the Functional Capacity of Hemodialysis Patients
|
N/A | |
Completed |
NCT01859871 -
Evaluation of a Website on Living Kidney Donation for Hispanics
|
N/A | |
Completed |
NCT00649298 -
A Clinical Trial of IntensiVE Dialysis
|
Phase 4 | |
Recruiting |
NCT05836220 -
Parathyroid Hormone (PTH) Attenuation Trial in Hemodialysis-2
|
Phase 3 | |
Completed |
NCT04912024 -
Comparative Outcome Measures of Patients Receiving Acute Renal ThErapy Study
|
||
Completed |
NCT01530945 -
Mapping Multidimensional Illness Trajectories of Patients With End-stage Kidney Disease
|
N/A | |
Completed |
NCT04815850 -
Phenotyping Seroconversion Following Vaccination Against COVID-19 in Patients on Haemodialysis Study
|
||
Recruiting |
NCT05738330 -
Symptom Monitoring in Hemodialysis
|
N/A | |
Completed |
NCT02475551 -
Study to Evaluate the Safety, Tolerability, Efficacy and PK of IdeS in Kidney Transplantation
|
Phase 2 | |
Active, not recruiting |
NCT05418816 -
SelfWrap-Assisted Arteriovenous Fistulas
|
N/A |